Ratings by TD Cowen (Tara Bancroft)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/2/2026 | EyePoint Inc. | EYPT | Downgrade | Hold (Buy) |
4.50 (4.58) |
1.78% | Details | |
| 8/22/2026 | Nektar Therapeutics | NKTR | New Coverage | Buy (N/A) |
74.53 (71.75) |
-3.73% | Details | |
| 8/22/2026 | Janux Therapeutics | JANX | New Coverage | Buy (N/A) |
17.28 (18.89) |
9.32% | Details | |
| 8/22/2026 | Incyte | INCY | New Coverage | Buy (N/A) |
127.22 (125.01) |
-1.74% | Details | |
| 8/11/2026 | Valneva SE | VALN | New Coverage | Buy (N/A) |
5.30 (6.57) |
23.96% | Details | |
| 8/5/2026 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 8/3/2026 | Lantheus Holdings | LNTH | Downgrade | Hold (Buy) |
99.64 (100.88) |
1.24% | Details | |
| 8/3/2026 | Rocket Pharmaceuticals | RCKT | Maintain | Hold (N/A) |
|
Details | ||
| 7/20/2026 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2026 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2026 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2026 | TG Therapeutics | TGTX | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2026 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 6/15/2026 | Kalaris | KLRS | New Coverage | Buy (N/A) |
4.33 (3.92) |
-9.47% | Details | |
| 4/27/2026 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Buy (N/A) |
27.51 (25.57) |
-7.05% | Details | |
| 3/12/2026 | Nanobiotix S.A | NBTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/6/2026 | Day One Biopharmaceuticals | DAWN | Downgrade | Hold (Buy) |
12.78 (21.53) |
68.47% | Details | |
| 2/26/2026 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2026 | Protagonist Therapeutics | PTGX | Maintain | (N/A) |
|
Details | ||
| 2/25/2026 | Vaxcyte | PCVX | Maintain | (N/A) |
|
Details | ||
| 2/6/2026 | Nanobiotix S.A | NBTX | New Coverage | Buy (N/A) |
21.03 (39.29) |
86.83% | Details | |
| 1/29/2026 | Day One Biopharmaceuticals | DAWN | Maintain | Buy (N/A) |
|
Details | ||
| 1/29/2026 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 1/29/2026 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2026 | Day One Biopharmaceuticals | DAWN | New Coverage | Buy (N/A) |
11.33 (12.78) |
12.8% | Details | |
| 12/30/2025 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 12/19/2025 | EyePoint Inc. | EYPT | New Coverage | Buy (N/A) |
16.66 (4.50) |
-72.99% | Details | |
| 12/19/2025 | Rocket Pharmaceuticals | RCKT | New Coverage | Hold (N/A) |
3.27 (3.73) |
14.07% | Details | |
| 12/16/2025 | Ocular Therapeutix | OCUL | Maintain | Buy (N/A) |
|
Details | ||
| 11/7/2025 | Protagonist Therapeutics | PTGX | Maintain | (N/A) |
|
Details | ||
| 10/30/2025 | Ocular Therapeutix | OCUL | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2025 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2025 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2025 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2025 | Ocular Therapeutix | OCUL | Maintain | Buy (N/A) |
|
Details | ||
| 7/9/2025 | Verona Pharma | VRNA | Downgrade | Hold (Buy) |
86.86 (106.91) |
23.08% | Details | |
| 5/12/2025 | Day One Biopharmaceuticals | DAWN | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2025 | Verona Pharma | VRNA | New Coverage | Buy (N/A) |
65.46 (86.86) |
32.69% | Details | |
| 4/23/2025 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2025 | Disc Medicine | IRON | New Coverage | Buy (N/A) |
54.46 (78.67) |
44.45% | Details | |
| 2/26/2025 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2024 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2024 | TG Therapeutics | TGTX | New Coverage | Buy (N/A) |
24.35 (56.09) |
130.35% | Details | |
| 10/14/2024 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 10/10/2024 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 9/24/2024 | Protagonist Therapeutics | PTGX | New Coverage | Buy (N/A) |
46.15 (146.49) |
217.42% | Details | |
| 9/16/2024 | Sutro Biopharma | STRO | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2024 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2024 | Bicycle Therapeutics | BCYC | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2024 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2024 | Sutro Biopharma | STRO | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2024 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 7/23/2024 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 7/23/2024 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2024 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 6/20/2024 | Ocular Therapeutix | OCUL | Upgrade | Buy (Hold) |
5.49 (10.57) |
92.53% | Details | |
| 6/14/2024 | Ocular Therapeutix | OCUL | Maintain | Hold (N/A) |
|
Details | ||
| 6/13/2024 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 6/7/2024 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2024 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 5/29/2024 | Ikena Oconology | IKNA | Maintain | Buy (N/A) |
|
Details | ||
| 5/28/2024 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 5/24/2024 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2024 | Ocular Therapeutix | OCUL | Maintain | Hold (N/A) |
|
Details | ||
| 4/29/2024 | Geron Corporation | GERN | New Coverage | Buy (N/A) |
3.79 (1.48) |
-60.95% | Details | |
| 1/16/2024 | Harpoon Therapeutics | HARP | Downgrade | Hold (Buy) |
22.45 (23.01) |
2.49% | Details | |
| 11/20/2023 | Harpoon Therapeutics | HARP | New Coverage | Buy (N/A) |
11.41 (23.01) |
101.67% | Details | |
| 8/21/2023 | Merus N.V. | MRUS | New Coverage | Buy (N/A) |
21.09 (90.00) |
326.74% | Details | |
| 8/31/2022 | Bicycle Therapeutics | BCYC | New Coverage | Buy (N/A) |
25.37 (4.10) |
-83.84% | Details |
